Creagan E T, Schaid D J, Hartmann L C, Loprinzi C L
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905.
Am J Clin Oncol. 1993 Jun;16(3):243-4. doi: 10.1097/00000421-199306000-00010.
Forty patients with measurable disseminated malignant melanoma and no prior chemotherapy received monthly DHAC, 5 g/m2/24 h, as a continuous infusion. Among 26 "good risk patients" (ECOG performance score 0, 1 and no prior biological therapy), we observed 3 objective regressions. Among 14 "poor-risk patients" (ECOG PS 2 or prior biological therapy), we observed no objective regressions. For all patients, median time to progression and survival were 1 month and 6.7 months, respectively. Transient pleuritic chest pain and mild nausea and vomiting were the most common complications. We were especially impressed with a complete response (CR) for 11+ months in a 43-year-old woman with extensive visceral metastases and another CR lasting > 4.7 months in a 36-year-old woman with nonvisceral metastatic disease. The absence of myelosuppression raises intriguing possibilities for combination regimens including DHAC in the management of malignant melanoma.
40例可测量的播散性恶性黑色素瘤患者且未接受过化疗，每月接受5 g/m²/24 h的DHAC持续静脉输注。在26例“低风险患者”（东部肿瘤协作组体能状态评分0、1且未接受过生物治疗）中，我们观察到3例客观缓解。在14例“高风险患者”（东部肿瘤协作组体能状态评分2或接受过生物治疗）中，未观察到客观缓解。所有患者的中位疾病进展时间和生存期分别为1个月和6.7个月。短暂性胸膜炎性胸痛以及轻度恶心和呕吐是最常见的并发症。我们对一名有广泛内脏转移的43岁女性出现11个多月的完全缓解以及一名有非内脏转移疾病的36岁女性出现持续超过4.7个月的完全缓解印象尤为深刻。未出现骨髓抑制为包括DHAC在内的联合方案用于恶性黑色素瘤的治疗带来了有趣的可能性。
